Form 4: Nurix Therapeutics CFO Hans van Houte Reports Stock Sales
SEC Form 4 Filing
Hans van Houte, CFO of Nurix Therapeutics, reports the sale of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 1, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold 3,377 shares of common stock at a weighted average price of $21.4255.
- An additional 100 shares were sold at $22.22.
- These transactions were executed under a pre-existing Rule 10b5-1 trading plan.
- Following these sales, van Houte directly owns 51,002 shares of Nurix Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral. This is a standard disclosure of stock sales by an executive under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to have pre-arranged trading plans to sell shares over time.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of stock sale transactions by Hans van Houte |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.